# US 10,946,034 B2 · Methods for the use of 5′-adenosine diphosphate ribose (ADPR)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,946,034 B2
- Document ID: US10946034B2
- Status: Granted
- Kind: B2
- Application number: 16/364,760
- Filed: 2019-03-26
- Published: 2019-10-03
- Granted: 2021-03-16
- Earliest claimed: 2018-03-27
- Assignees: Invirsa, Inc.
- Applicants: Invirsa, Inc.
- Inventors: Robert Shalwitz
- Web page: https://patentgrep.com/patent/US10946034B2

## CPC

- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 47/02: Inorganic compounds
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/22: for herpes viruses
- A61K 9/0043: {Nose}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to methods for the use of 5′-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.

## Claims

### Claim 1

A method for treating, managing, or preventing an RNA virus-related disease or condition in a patient, said method comprising administering to the patient an effective amount of 5′-adenosine diphosphate ribose (ADPR), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopologue, or polymorph thereof; wherein the patient has or is at risk of developing an RNA virus-related disease or condition; and
wherein the RNA virus-related disease or condition is caused by an RNA virus, wherein the RNA virus is human respiratory syncytial virus (HRSV).

### Claim 2 (depends on 1)

The method of claim 1, wherein the RNA virus-related disease or condition is epi-bulbar disease, conjunctivitis, keratitis, kerato-conjunctivitis, corneal abrasion, ulcerative infectious keratitis, epithelial keratitis, stromal keratitis, uveitis, acute glaucoma, blepharitis, otitis media, otitis externa, gingivitis, mucositis, pharyngitis, tonsillitis, rhinitis, sinusitis, laryngitis, croup, tracheitis, bronchitis, bronchiolitis, bronchiolar pneumonia, pneumonia, exacerbation of asthma, exacerbation of chronic obstructive pulmonary disease, exacerbation of emphysema, or exacerbation of a chronic lung disease.

### Claim 3 (depends on 2)

The method of claim 2, wherein the RNA virus-related disease or condition is conjunctivitis, keratitis, kerato-conjunctivitis, pharyngitis, tonsillitis, laryngitis, rhinitis, sinusitis, bronchitis, bronchiolitis, or pneumonia.

### Claim 4 (depends on 3)

The method of claim 3, wherein the RNA virus-related disease or condition is keratitis, conjunctivitis, or keratoconjunctivitis.

### Claim 5 (depends on 3)

The method of claim 3, wherein the RNA virus-related disease or condition is bronchitis, bronchiolitis, or pneumonia.

### Claim 6 (depends on 3)

The method of claim 3, wherein the RNA virus-related disease or condition is pharyngitis, tonsillitis, sinusitis, or laryngitis.

### Claim 7 (depends on 1)

The method of claim 1, wherein the administering is done by topical, oral, parenteral, mucosal, or inhalation route of administration.

### Claim 8 (depends on 1)

The method of claim 1, wherein the administering is done by inhalation administration.

### Claim 9 (depends on 7)

The method of claim 7, wherein the topical administration is to an interior cellular or tissue surface of the patient.

### Claim 10 (depends on 9)

The method of claim 9, wherein the topical administration is by aerosolization, nebulization, spray, oral delivery, intra-tracheal infusion, intra-bronchial, or infusion to a surface of the respiratory tract.

### Claim 11 (depends on 7)

The method of claim 7, wherein the topical administration is to an exterior cellular or tissue surface.

### Claim 12 (depends on 11)

The method of claim 11, wherein the exterior cellular or tissue surface is the surface of the skin, eye, nail, hair, or ear.

### Claim 13 (depends on 1)

The method of claim 1, wherein the administering is done by intravenous, intra-arterial, or intraductal infusion.

### Claim 14 (depends on 1)

The method of claim 1, wherein the patient is administered a pharmaceutical composition comprising ADPR, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopologue, or polymorph thereof, and an excipient, diluent, or carrier.

### Claim 15 (depends on 14)

The method of claim 14, wherein the pharmaceutical composition is in the form of a solution, suspension, emulsion, microemulsion, nanoemulsion, suppository, enema, syrup, elixir, dry powder aerosol, liquid aerosol, tablet, or dissolving media.

### Claim 16 (depends on 15)

The method of claim 15, wherein the dissolving media is a rapid dissolving tablet, film, or strip.

### Claim 17 (depends on 15)

The method of claim 15, wherein the pharmaceutical composition is in the form of a solution.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1 and 2-17, wherein the ADPR or pharmaceutical composition comprising ADPR is administered in combination with another medicament.

### Claim 19 (depends on 18)

The method of claim 18, wherein the another medicament is an antiviral compound.

### Claim 20 (depends on 1)

The method of claim 1, wherein the ADPR is in the form of its sodium salt.

### Claim 21 (depends on 1)

The method of claim 1, wherein the ADPR is in the form of its disodium salt.

### Claim 22 (depends on 1)

The method of claim 1, wherein the ADPR is in the form of its lithium salt.

### Claim 23 (depends on 1)

The method of claim 1, wherein the ADPR is in the form of its dilithium salt.